Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

REAL WORLD DATA COLLECTION AMONG PEDIATRIC NEUROBLASTOMA PATIENTS TREATED WITH LORLATINIB THROUGH EXPANDED ACCESS PROGRAM

The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Inclusion Criteria:

• Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.
• HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
• Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

• Any patient who does not meet any of the inclusion criteria defined in the previous section.